A novel, conformation‐specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties
- 19 March 2007
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 21 (9) , 2124-2134
Abstract
The orthosteric agonist neurokinin A (NKA) interacts with the tachykinin NK2 receptors (NK2Rs) via an apparent sequential binding process, which stabilizes the receptor in at least two different active conformations (A1L and A2L). The A1L conformation exhibits fast NKA dissociation kinetics and triggers intracellular calcium elevation;the A2L conformation exhibits slow NKA dissociation kinetics and triggers cAMP production. The new compound LPI805 is a partial and noncompetitive inhibitor of NKA binding to NK2Rs. Analysis of NKA dissociation in the presence of LPI805 suggests that LPI805 decreases the number of NKA‐NK2R complexes in A2L conformation while increasing those in the A1L conformation. Analysis of signaling pathways of NK2Rs shows that LPI805 dramatically inhibits the NKA‐induced cAMP response while slightly enhancing the NKA‐induced calcium response. Analysis of NKA association kinetics reveals that LPI805 promotes strong and specific destabilization of the NKA‐NK2R complexes in the A2L conformation whereas access of NKA to the A1L conformations is unchanged. Thus, to our knowledge, LPI805 is the first example of a conformation‐specific allosteric antagonist of a G‐protein‐coupled receptor. This work establishes the use of allosteric modulators in order to promote functional selectivity on certain agonist‐receptor interactions.–Maillet E. L., Pellegrini, N., Valant, C., Bucher, B., Hibert, M., Bourguignon J‐J., Galzi J‐L. A novel, conformation‐specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J. 21, 2124–2134 (2007)Keywords
Funding Information
- Division of Arctic Sciences
- College of Natural Resources and Sciences, Humboldt State University
This publication has 37 references indexed in Scilit:
- Keynote review: Allosterism in membrane receptorsDrug Discovery Today, 2006
- G protein‐coupled receptors: a count of 1001 conformationsFundamental & Clinical Pharmacology, 2005
- Mutations in the Extracellular Amino-terminal Domain of the NK2 Neurokinin Receptor Abolish cAMP Signaling but Preserve Intracellular Calcium ResponsesJournal of Biological Chemistry, 2002
- GPCR Drug Discovery Through the Exploitation of Allosteric Drug Binding SitesReceptors and Channels, 2002
- G Protein-Coupled Receptor Allosterism and ComplexingPharmacological Reviews, 2002
- Two Active Molecular Phenotypes of the Tachykinin NK1 Receptor Revealed by G-protein Fusions and MutagenesisJournal of Biological Chemistry, 2001
- Dual Signaling Regulated by Calcyon, a D1 Dopamine Receptor Interacting ProteinScience, 2000
- Agonist-receptor efficacy II: agonist trafficking of receptor signalsTrends in Pharmacological Sciences, 1995
- A potent and selective non-peptide antagonist of the neurokinin a (NK2) receptorLife Sciences, 1992
- Interaction of a fluorescent agonist with the membrane-bound acetylcholine receptor from Torpedomarmorata in the millisecond time range: Resolution of an “intermediate” conformational transition and evidence for positive cooperative effectsBiochemical and Biophysical Research Communications, 1980